Discovery/R&D

  1. Academia + Industry with BridgeBio's Dr. Michael Henderson 6/21/2021

    BridgeBio has a whopping 30+ pre-clinical to clinical-stage candidates in its pipeline representing an impressive array of modalities and targets. It boasts a couple of commercial wins under its belt. The company is no stranger to developing business strategies for success. Central to that success are partnerships with scientists and researchers to fuel pipeline expansion. On this episode of The Business of Biotech, BridgeBio Chief Business Officer Michael Henderson, M.D. walks us through the formula behind the company's academia-led growth strategy.

  2. Expanding The Proteome with ProFound's John Lepore, M.D. 7/28/2024

    Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question:  What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome.

  3. Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, Ph.D. 4/10/2024

    Ampersand Biomedicines CEO Jason Gardner, Ph.D. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use.

  4. Antibodies For Severe Allergies With IgGenix's Jessica Grossman, M.D. 4/4/2022

    In this wide-ranging discussion, IgGenix CEO Jessica Grossman, M.D. discusses the application of and market opportunity for antibody therapy for severe allergies, the gender gap in the biopharma c-suite, why women work harder than men, what it means to be a female biopharma leader, and IgGenix's approach at isolating and re-engineering allergen-specific IgE antibodies into IgG antibodies designed to alleviate — and possibly prevent — allergic cascade.

  5. ML-Enabled Drug Discovery With LabGenius' James Field, Ph.D. 7/6/2023

    We explore the intersection of tech and bio with Dr. James Field, founder and CEO of LabGenius. If you're concerned with what ML will do to — or for — your biopharma business, don't miss this episode

  6. RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D. 1/12/2025

    In close partnership with Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of Biotech, we team up once again with Advancing RNA's Anna Rose Welch to learn about the venture, dubbed the Johns Hopkins University RNA Innovation Center.

  7. Commensal Viral Vectors With Ring Therapeutics' Tuyen Ong, M.D. 4/12/2022

    When Tuyen Ong was a child, he and his family escaped Vietnam by boat in the dead of the night, bound for an Indonesian refugee camp. They spent a year in that camp before emigrating to the U.K., where Ong’s underprivileged adolescence found him growing up in the projects of London. Against the odds, Ong worked his way to UCL for an education that culminated with an M.D. Today, he’s CEO of Ring Therapeutics, a promising emerging biotech backed by Flagship Pioneering, the kingmaker behind the rise of Moderna. On this episode of the Business of Biotech, Ong shares on his challenging formative years, the unspoken love between a father and son, facing down racism as a poor Chinese kid in Vietnam and London, and how those experiences shape his leadership at Ring. Oh, and we talk about some pretty cool science, too.

  8. Live Biologics & The Microbiome With 4D pharma's Duncan Peyton 5/9/2022

    4D pharma's flagship early-stage clinical candidates are live biotherapeutics, a relatively new class of biologics that seek to impact disease state by modulating the microbiome. CEO Duncan Peyton is leading the effort to understand how the health of the microbiome relates to a wide range of diseases, including immuno-oncology, central nervous system disorders, respiratory disease, auto immune indications, and gastro intestinal disease. 4D pharma is even working on a live biotherapeutic vaccine platform. Join Duncan on this episode of the Business of Biotech as we discuss this new frontier of therapeutic exploration.

  9. Precision Approach To Infectious Disease With Locus Biosciences' Paul Garofolo 1/13/2022

    Locus Biosciences CEO Paul Garofolo built his biotech leadership career on the back of an MIS degree, having learned the business from the inside out via the tentacles of the IT networks at companies including Genentech, The Broadlane Group, Valeant Pharmaceuticals and Patheon. On today's episode of the Business of Biotech, Garofolo shares how a technologist's approach has helped shape the effort to develop precision therapeutics for infectious diseases at Locus, the company's decision to build its own cGMP manufacturing facility in Research Triangle, and the massive business opportunity the field addresses in the effort to overcome antibiotic resistance.

  10. Turning The Liver Into A mAb Factory With Homology's Arthur Tzianabos, Ph.D. 11/15/2021

    Homology Medicines' approaches to gene therapy and gene editing have the potential to seriously disrupt both the cell/gene therapy space \_and\_ the mAb manufacturing and administration paradigms as we know them. On this episode of the Business of Biotech, Homology President & CEO Arthur Tzianabos, Ph.D. shares the company's approach and supports its rationale for investing in its own development and manufacturing capacity.